M
Mosanna Therapeutics
Improving the lifes of patiens with metabolic obstructive sleep apnea
About Mosanna Therapeutics
Mosanna Therapeutics is a clinical-stage biotechnology company founded in 2022, with dual headquarters in Redwood City, California, and Basel, Switzerland. The company was co-founded by Jonathan Talbot and the venture capital fund Forty51 Ventures. Talbot, who initially served as CEO, has a background in the pharmaceutical industry and started Mosanna to develop promising drugs that larger companies had shelved. He identified a clinically de-risked small molecule, originally from Sanofi, and built the company around optimizing its delivery to treat obstructive sleep apnea (OSA). In June 2025, veteran biotech leader David Weber, PhD, was appointed President and CEO to guide the company through its next growth phase, including clinical development.
The company is focused on developing a pharmaceutical alternative to the mechanical devices that currently dominate the OSA market, which affects an estimated one billion people globally. Mosanna's business model centers on the research and development of novel therapeutics, funded by venture capital. It aims to address the significant unmet need among patients who cannot tolerate standard treatments like CPAP machines. As a clinical-stage entity, its revenue generation will depend on future product approval and commercialization. The company has successfully raised significant capital, including an $80 million Series A round in June 2025, to advance its lead candidate through clinical trials. This funding was co-led by Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Broadview Ventures, and Norwest.
Mosanna's lead product is MOS118, a small molecule administered as a nighttime nasal spray. The therapy is designed to restore the body's natural reflex to keep the upper airway open during sleep, addressing the root neurological and muscular dysfunction of OSA rather than just the mechanical obstruction. This approach targets the muscles responsible for maintaining airway patency, which exhibit decreased activity in OSA patients during sleep. By delivering the drug directly to the nasal cavity, MOS118 is engineered to act locally in the upper airway throughout the night. The primary benefit is providing a non-invasive, user-friendly treatment that can improve adherence and, consequently, long-term health outcomes for a patient population at high risk for cardiovascular and metabolic comorbidities.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2025 | $80M | $320M | Norwest Venture Partners · Broadview Ventures · HTGF · Supermoon Capital | ↗ |
| SEEDOther financing | Apr 2023 | — | — | HTGF · Supermoon Capital · Forty51 Ventures | ↗ |
Growth signals
Latest recorded traffic for Mosanna Therapeutics is 2.1K monthly website visits, up 2525% over the last three months. Mosanna Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Mosanna Therapeutics in the Basel ecosystem
The Mosanna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Forty51 Ventures
HTGF
Supermoon Capital
Series A5 investors entered at this stage
Norwest Venture Partners
Broadview Ventures
EQT Life Sciences
Forbion Capital Partners
Pivotal BioVenture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mosanna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mosanna Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










